[go: up one dir, main page]

SG11201903344XA - Non-human animals having an engineered immunoglobulin lambda light chain locus - Google Patents

Non-human animals having an engineered immunoglobulin lambda light chain locus

Info

Publication number
SG11201903344XA
SG11201903344XA SG11201903344XA SG11201903344XA SG11201903344XA SG 11201903344X A SG11201903344X A SG 11201903344XA SG 11201903344X A SG11201903344X A SG 11201903344XA SG 11201903344X A SG11201903344X A SG 11201903344XA SG 11201903344X A SG11201903344X A SG 11201903344XA
Authority
SG
Singapore
Prior art keywords
rover
road
tarrytown
saw mill
human
Prior art date
Application number
SG11201903344XA
Inventor
Chunguang Guo
Faith Harris
Vera Voronina
John Mcwhirter
Natasha Levenkova
Lynn Macdonald
Naxin Tu
Andrew Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201903344XA publication Critical patent/SG11201903344XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/128691 Al 12 July 2018 (12.07.2018) WIP0 1 PCT (51) International Patent Classification: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, A01K 67/027 (2006.01) C12N 15/85 (2006.01) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, C12N 15/90 (2006.01) CO7K 16/00 (2006.01) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: (84) Designated States (unless otherwise indicated, for every PCT/US2017/060006 kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 03 November 2017 (03.11.2017) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (25) Filing Language: English EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (30) Priority Data: KM, ML, MR, NE, SN, TD, TG). 62/417,845 04 November 2016 (04.11.2016) US 62/567,932 04 October 2017 (04.10.2017) US Declarations under Rule 4.17: — (71) Applicant: REGENERON PHARMACEUTICALS, of inventorship (Rule 4.17(iv)) INC. [US/US]; 777 Old Saw Mill Rover Road, Tarrytown, Published: NY 10591-6706 (US). — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the (72) Inventors: GUO, Chunguang; c/o Regeneron Pharmaceu- claims and to be republished in the event of receipt of ticals, Inc., 777 Old Saw Mill Rover Road, Tarrytown, NY amendments (Rule 48.2(h)) 10591 (US). HARRIS, Faith; c/o Regeneron Pharmaceuti- cals, Inc., 777 Old Saw Mill Rover Road, Tarrytown, NY = 10591 (US). VORONINA, Vera; c/o Regeneron Pharma- _ ceuticals, Inc., 777 Old Saw Mill Rover Road, Tarrytown, NY 10591 (US). MCWHIRTER, John; c/o Regeneron =_ — Pharmaceuticals, Inc., 777 Old Saw Mill Rover Road, Tar- rytown, NY 10591 (US). LEVENKONA, Natasha; c/o Re- generon Pharmaceuticals, Inc., 777 Old Saw Mill Rover = Road, Tarrytown, NY 10591 (US). MACDONALD, Lynn; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill Rover Road, Tarrytown, NY 10591 (US). TU, Naxin; c/o = _ Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill Rover = Road, Tarrytown, NY 10591 (US). MURPHY, Andrew, _ J.; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill = = Rover Road, Tarrytown, NY 10591 (US). Agent: SCHONEWALD, Stephanie, L.; Choate, Hall & (74) Stewart LLP, Two International Place, Boston, MA 02110 = (US). = (81) Designated States (unless otherwise indicated, for every — kind of national protection available): AE, AG, AL, AM, = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = — 1-1 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, Il ON (54) Title: NON-HUMAN ANIMALS HAVING AN ENGINEERED IMMUNOGLOBULIN LAMBDA LIGHT CHAIN LOCUS GO (57) : Non-human animals (and/or non-human cells) and methods of using and making the same are provided, which non- e\"' human animals (and/or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). 1-1 —. Non-human animals described herein express antibodies that contain human Igk light chains, in whole or in part. In particular, non- GO human animals provided herein are, in some embodiments, characterized by expression of antibodies that contain human Ig?. light 1-1 © chains, in whole or in part, that are encoded by human Igk light chain-encoding sequences inserted into an endogenous Igk light chain f'1 locus of said non-human animals. Methods for producing antibodies from non-human animals are also provided. 0
SG11201903344XA 2016-11-04 2017-11-03 Non-human animals having an engineered immunoglobulin lambda light chain locus SG11201903344XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662417845P 2016-11-04 2016-11-04
US201762567932P 2017-10-04 2017-10-04
PCT/US2017/060006 WO2018128691A1 (en) 2016-11-04 2017-11-03 Non-human animals having an engineered immunoglobulin lambda light chain locus

Publications (1)

Publication Number Publication Date
SG11201903344XA true SG11201903344XA (en) 2019-05-30

Family

ID=62025924

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913483XA SG10201913483XA (en) 2016-11-04 2017-11-03 Non-human animals having an engineered immunoglobulin lambda light chain locus
SG11201903344XA SG11201903344XA (en) 2016-11-04 2017-11-03 Non-human animals having an engineered immunoglobulin lambda light chain locus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201913483XA SG10201913483XA (en) 2016-11-04 2017-11-03 Non-human animals having an engineered immunoglobulin lambda light chain locus

Country Status (26)

Country Link
US (2) US10820582B2 (en)
EP (4) EP3407709B9 (en)
JP (5) JP6884860B2 (en)
KR (4) KR102492433B1 (en)
CN (2) CN114369157A (en)
AU (2) AU2017391167B2 (en)
BR (1) BR112019008675A2 (en)
CA (1) CA3038720A1 (en)
CY (2) CY1123491T1 (en)
DK (3) DK3407709T3 (en)
ES (3) ES2823305T3 (en)
FI (1) FI4082334T3 (en)
HR (3) HRP20250695T1 (en)
HU (3) HUE061980T2 (en)
IL (2) IL308197A (en)
LT (3) LT3766343T (en)
MA (2) MA44091A (en)
MX (2) MX385857B (en)
PL (3) PL3766343T3 (en)
PT (3) PT3766343T (en)
RS (3) RS66884B1 (en)
RU (2) RU2021129958A (en)
SG (2) SG10201913483XA (en)
SI (3) SI3407709T1 (en)
SM (3) SMT202200259T1 (en)
WO (1) WO2018128691A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10881084B2 (en) 2010-07-26 2021-01-05 Trianni, Inc Transgenic animals and methods of use
HRP20192218T1 (en) * 2012-02-01 2020-03-06 Regeneron Pharmaceuticals, Inc. Humanized mice that express heavy chains containing vl domains
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
RS66884B1 (en) 2016-11-04 2025-07-31 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain locus
DK3772927T3 (en) 2018-03-24 2025-02-17 Regeneron Pharma Genetically modified mice or rats for generating therapeutic antibodies against peptide-MHC complexes, method of preparation and uses thereof
KR20250121150A (en) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 Humanized rodents for testing therapeutic agents
IL318469A (en) * 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of engineered dh-dh rearrangement and uses thereof
SG11202107589PA (en) 2019-02-22 2021-08-30 Regeneron Pharma Rodents having genetically modified sodium channels and methods of use thereof
DK3993623T3 (en) * 2019-07-01 2025-05-26 Zoetis Services Llc Transgenic rodents and methods of using them
EP4158034A4 (en) * 2020-06-02 2024-07-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS HAVING A LIGHT-CHAIN IMMUNOGLOBULIN LOCUS
IL301137A (en) 2020-09-11 2023-05-01 Regeneron Pharma Identification and production of antigen-specific antibodies
KR20230147048A (en) 2020-12-16 2023-10-20 리제너론 파마슈티칼스 인코포레이티드 Mice expressing humanized Fc alpha receptors
US20240317849A1 (en) 2020-12-23 2024-09-26 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
CA3197426A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
GB202217978D0 (en) * 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012227A1 (en) * 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1461442T3 (en) 2001-11-30 2017-12-04 Amgen Fremont Inc Transgenic animals with human Ig lambda light chain genes
MXPA06000562A (en) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Humanized immunoglobulin loci.
MX2008014804A (en) 2006-06-02 2009-01-27 Regeneron Pharma High affinity antibodies to human il-6 receptor.
PL2346994T3 (en) 2008-09-30 2022-04-19 Ablexis, Llc Knock-in mice for the production of chimeric antibodies
US20110314563A1 (en) * 2008-12-18 2011-12-22 Kingdon Craig R Antibody production
DK2564695T3 (en) * 2009-07-08 2015-05-26 Kymab Ltd Animal models and therapeutic molecules
RU2425880C2 (en) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Method of producing transgene mice
WO2011115476A1 (en) 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
WO2011163314A1 (en) 2010-06-22 2011-12-29 Regeneron Pharmaceuticals, Inc. Hybrid light chain mice
LT2578688T (en) 2011-02-25 2019-11-11 Regeneron Pharma ADAM6 MOUSE
LT2627773T (en) 2011-10-17 2017-12-27 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR102038974B1 (en) * 2011-12-20 2019-10-31 리제너론 파마슈티칼스 인코포레이티드 Humanized light chain mice
AU2014218931C1 (en) 2013-02-20 2020-05-14 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
DK2840892T3 (en) * 2013-02-20 2018-07-23 Regeneron Pharma Non-human animals with modified heavy chain immunoglobulin sequences
US9788534B2 (en) * 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
CA2925723A1 (en) * 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
MX388127B (en) 2013-12-11 2025-03-19 Regeneron Pharma METHODS AND COMPOSITIONS FOR THE TARGETED MODIFICATION OF A GENOME.
CA2950173C (en) 2014-06-06 2023-10-10 Regeneron Pharmaceuticals, Inc. Methods and compositions for modifying a targeted locus
ES2781323T3 (en) 2014-06-23 2020-09-01 Regeneron Pharma Nuclease-mediated DNA assembly
ES2731437T3 (en) 2014-11-21 2019-11-15 Regeneron Pharma Methods and compositions for directed genetic modification through the use of guide RNA pairs
CN107208113A (en) 2014-12-19 2017-09-26 瑞泽恩制药公司 Method and composition for carrying out targeting genetic modification by the multiple targeting of single step
RS66884B1 (en) 2016-11-04 2025-07-31 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain locus

Also Published As

Publication number Publication date
EP3407709B9 (en) 2021-10-06
SI3766343T1 (en) 2022-06-30
SMT202500204T1 (en) 2025-07-22
NZ753456A (en) 2021-08-27
RU2757665C2 (en) 2021-10-20
AU2017391167B2 (en) 2024-02-15
LT3766343T (en) 2022-06-10
AU2024200582A1 (en) 2024-03-28
KR20210134059A (en) 2021-11-08
CY1123491T1 (en) 2022-03-24
HRP20250695T1 (en) 2025-08-01
PL3407709T3 (en) 2021-01-11
EP3766343A1 (en) 2021-01-20
MA53935A (en) 2021-12-22
RS60886B1 (en) 2020-11-30
KR20230020550A (en) 2023-02-10
SG10201913483XA (en) 2020-03-30
RS66884B1 (en) 2025-07-31
HUE052087T2 (en) 2021-04-28
BR112019008675A2 (en) 2019-07-09
ES2823305T3 (en) 2021-05-06
JP2022130725A (en) 2022-09-06
DK4082334T3 (en) 2025-06-02
SMT202200259T1 (en) 2022-07-21
EP4082334A1 (en) 2022-11-02
EP3407709B1 (en) 2020-07-29
KR102492433B1 (en) 2023-01-30
KR20190076024A (en) 2019-07-01
IL266282B2 (en) 2024-04-01
WO2018128691A1 (en) 2018-07-12
HUE061980T2 (en) 2023-09-28
JP7386292B2 (en) 2023-11-24
PL4082334T3 (en) 2025-08-11
MX2019005256A (en) 2019-08-05
IL266282A (en) 2019-06-30
US20180125043A1 (en) 2018-05-10
FI4082334T3 (en) 2025-06-10
PT3766343T (en) 2022-05-30
KR102658529B1 (en) 2024-04-19
EP3766343B1 (en) 2022-05-11
RU2019112589A3 (en) 2021-03-30
EP4567119A3 (en) 2025-09-24
CN109996441B (en) 2022-02-08
CN114369157A (en) 2022-04-19
US10820582B2 (en) 2020-11-03
EP4082334B1 (en) 2025-03-26
HRP20220888T1 (en) 2022-10-28
RS63390B1 (en) 2022-08-31
US20210029978A1 (en) 2021-02-04
CN109996441A (en) 2019-07-09
ES2915609T3 (en) 2022-06-23
JP6884860B2 (en) 2021-06-09
MA44091A (en) 2018-10-24
ES3035365T3 (en) 2025-09-02
CY1125474T1 (en) 2025-05-09
JP2020501516A (en) 2020-01-23
JP2025166207A (en) 2025-11-05
IL266282B1 (en) 2023-12-01
EP3407709A1 (en) 2018-12-05
EP4567119A2 (en) 2025-06-11
HUE071595T2 (en) 2025-09-28
PL3766343T3 (en) 2022-09-26
MX2021010556A (en) 2021-10-01
KR20240055863A (en) 2024-04-29
PT4082334T (en) 2025-05-21
MX385857B (en) 2025-03-18
HRP20201403T1 (en) 2020-11-27
CA3038720A1 (en) 2018-07-12
DK3766343T3 (en) 2022-06-20
US12433264B2 (en) 2025-10-07
LT3407709T (en) 2020-10-12
JP2023053400A (en) 2023-04-12
KR102319069B1 (en) 2021-11-01
PT3407709T (en) 2020-08-20
JP2021090455A (en) 2021-06-17
IL308197A (en) 2024-01-01
RU2021129958A (en) 2021-11-02
SMT202000558T1 (en) 2020-11-10
SI4082334T1 (en) 2025-06-30
AU2017391167A1 (en) 2019-05-30
WO2018128691A8 (en) 2019-02-28
DK3407709T3 (en) 2020-08-31
SI3407709T1 (en) 2020-10-30
RU2019112589A (en) 2020-12-04
LT4082334T (en) 2025-05-26

Similar Documents

Publication Publication Date Title
SG11201903344XA (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
SG11201810757YA (en) Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
SG11201407370QA (en) Humanized il-7 rodents
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201909322VA (en) Treatment of asthma with anti-tslp antibody
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201908658TA (en) Nucleobase editors comprising nucleic acid programmable dna binding proteins
SG11201407789RA (en) Humanized non-human animals with restricted immunoglobulin heavy chain loci
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201909203WA (en) Tissue selective transgene expression
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201906319XA (en) Compositions and methods for the depletion of cd137+ cells
SG11201901961SA (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201408153YA (en) Prostate-specific membrane antigen antibody drug conjugates
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201806176PA (en) Non-human animals having an engineered angptl8 gene